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carried out independently by 2 researchers. We used tools of Scottish Intercollegiate 
Guidelines Networks (SIGN) for assessment of the quality of studies. Results: The 
effectiveness of the ST2 was assessed by means of association with prognosis(risk 
ratio (RR) or odds ratio (OR), accuracy of forecasting of the prognosis, stratification of 
risk), correlation with the comparative test and relevance with clinical symptoms. 
The RR or OR of the death arising from ST2 was 1.01~4.56, the RR of hospitalization 
was 1.054~2.4. On the other hand, RR of hospitalization of BNP was 1.15~2.0, the RR 
or OR of death arising from NT pro-BNP was 0.19~1.241. The sensitivity/specificity 
of the test was 64~87%/51~82% and AUC values were 0.689~0.84. The stratification 
of risk (Net Reclassification Improvement, NRI) on the death rate were reported to 
be significant at 9.4 and 9.9 in the 2 studies, but 1 study reported that stratification 
of risk of the death rate was 0.049 and stratification of risk of hospitalization rate 
was 0.0638. The correlation coefficients with BNP was 0.16~0.409 and with NT pro-
BNP was 0.28~0.523. The correlation coefficient with the peak VO2was 0.30 and with 
6-minute walk distance was 0.22. ConClusions: The ST2 is effective in determining 
the prognosis of patients with heart failure.
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objeCtives: Pharmacists, working as part of the multidisciplinary team, have a 
relevant role in improving clinical outcomes through providing educational inter-
vention, medicine management intervention, or a combination of both. The purpose 
of this study was to determinate the impact of a telephone counseling intervention 
administered bi-monthly by pharmacist on patients’ beliefs about antihyperten-
sive medicines and blood pressure control. Methods: Subjects were selected on 
a time frame of two months according to their attendance to the Centre for the 
Diagnosis and Therapy of Arterial Hypertension of Cardarelli Hospital of Naples, 
located in the South of Italy. Participants were randomly assigned to either control 
group (usual care) or intervention group (educational intervention). The study was 
developed in the framework of the Multidisciplinary Health Care Team (GOIP) for 
Diagnosis and Therapy of Arterial Hypertension activities. The intervention con-
sisted of an educational/counseling session based on patients’ needs assessment 
and provided by a pharmacist bi-monthly for one year via telephone. Results: 
A total of 164 patients (80 in the control group, CG, and 84 in the intervention 
group, IG) were recruited. At the end of follow-up, the reduction in SBP and DPB 
was significant in IG (p< 0.001) and there were also significant differences between 
IG and CG for both Necessity and Concern score (t= 5.74, p< 0.001; t= -7.86, p< 0.001 
respectively). Patients were divided into four attitudinal groups based on their BMQ 
results and data showed that at t= 12 83,3% of IG patients was “Accepting” and 15.5% 
was “Ambivalent”. None “Skeptical” patients were found in the IG and only 1,2% was 
“Indifferent”. ConClusions: Telephone-administered pharmacist intervention can 
improve BP control modifying patients beliefs and concerns about treatments, as 
well as involving patients as participants in the management of their health.
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bACkgRound: Current guidelines recommend a minimum of 3 months’ antico-
agulation (AC) following venous thromboembolism (VTE). The decision to prolong 
treatment depends on clinicians’ perception of benefit-risk, patient characteris-
tics, and preferences. As evidence is limited for the optimal duration of therapy, 
considerable variability exists in routine care. objeCtives: To describe the duration 
of AC following VTE in clinical practice in England and identify factors associated 
with longer duration. Methods: Retrospective study of all VTE events between 1 
April 2008 and 31 March 2012 in linked Clinical Practice Research Datalink/Hospital 
Episode Statistics databases. We defined VTEs by Read or ICD-10 codes with antico-
agulant prescription within 45 days after VTE or hospital discharge. We used multi-
variate Cox regression to identify factors associated with AC duration (event= end of 
AC). Results: Of 11,353 VTEs, 45.0% were PEs and 48.5% were in men. Mean patient 
age was 63.9 years. Median AC duration was 219 days. In the Cox model, previous VTE 
was strongly associated with increased AC duration (HR: 0.46 [95%CI 0.42-0.50]). Other 
factors associated with longer AC duration were age > 40 (vs ≤ 40, 41-64: 0.82 [0.76-0.89]; 
65-79: 0.74 [0.68-0.80]; ≥ 80: 0.82 [0.75-0.90]), PE (vs DVT, 0.71 [0.68-0.75]), active cancer 
(vs unprovoked VTE, 0.86 [0.80-0.92]), hospitalisation (vs no hospitalisation, leading 
to hospitalisation: 0.81 [0.77-0.85], during hospitalisation: 0.72 [0.66-0.79]), and history 
of systemic arterial thromboembolism (0.72 [0.56-0.91]). Other factors retained by the 
Cox model were gender, body mass index, geographic region, and previous major 
bleeding. ConClusions: In routine practice in England, most patients received more 
than 6 months of AC therapy after VTE. Factors associated with prolonged AC cor-
responded to risk factors commonly thought to increase VTE recurrence. Consensus 
concerning the optimal length of AC treatment following acute VTE (beyond 3 months) 
may help to minimize variability in patient care in the future.
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objeCtives: It is well-known that stroke is one of the primary causes of death 
with low survival rates in Turkey. This study investigates how many months 
aggressive payer policies encouraging VKA prescribing are expected across the EU5, 
together with extended pricing and reimbursement negotiations following each 
NOAC label expansion, in order to manage healthcare budgets.
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objeCtives: To establish whether identification of patients with statin-associated 
symptoms (SAS), particularly muscle-related symptoms (MRS) in real-world prac-
tice is aligned with the latest clinical consensus. Methods: A web-based survey 
was conducted in France, Germany, Italy, the Netherlands, Poland, Spain, Sweden, 
and the UK in February–March 2014. Sixty clinicians per country answered ques-
tions about clinical criteria used to identify patients with SAS. These criteria from 
real-world practice were compared with those recommended in the 2015 European 
Atherosclerosis Society Consensus Panel Statement (EASCPS) to explore their align-
ment. Results: Overall, 319 clinicians (76% cardiologists) completed the survey. 
Almost all clinicians (average 98%; range across countries [RAC] 97–100%) saw and 
considered MRS in patients receiving statins to indicate SAS. Across countries, an 
average of 69% of clinicians reported testing for elevated creatine kinase (CK) lev-
els in all patients newly prescribed statins; an average of 52% reported testing in 
patients who displayed MRS. On average, 77% of clinicians (RAC 68–85%) reported 
trying ≥ 2 statins before considering MRS to be SAS; 65% (RAC 57–73%) tried ≥ 3 
statins. Most clinicians (average 74%; RAC 63–85%) reported rechallenging patients 
with the same statin to confirm whether MRS were SAS. Of those who did not 
rechallenge, 61% (RAC 50–67%) reported discontinuing the statin to test whether 
MRS resolved, and an average of 38% (RAC 32–45%) reported using a combination 
of rechallenging, discontinuing, and lowering the dose of statin to confirm SAS. Of 
the reported criteria used for determining SAS, CK testing upon MRS and trial of ≤ 3 
statins are consistent with the latest EASCPS, although routine CK testing and statin 
rechallenge are not fully consistent. ConClusions: This survey suggests that the 
clinical criteria used to identify patients with SAS across eight European countries 
are broadly consistent with the current clinical consensus in Europe.
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objeCtives: To compare the management of statin-treated patients with hyper-
cholesterolemia and statin-associated symptoms (SAS) in real-world practice 
across eight European countries with the latest European Atherosclerosis Society 
Consensus Panel Statement (EASCPS) and decisions of national health technol-
ogy assessment (HTA) agencies. Methods: A web-based survey was conducted 
in France, Germany, Italy, the Netherlands, Poland, Spain, Sweden, and the UK in 
February–March 2014. Sixty clinicians (specialists and general/family physicians, 2:1 
ratio) per country answered questions about the management of patients with SAS. 
Targeted literature searches were performed (June 2015) to identify HTA decisions 
before and after the survey for comparison with survey outcomes. Results: 
Overall, 319 clinicians (76% cardiologists) completed the survey. An average of 58% 
of clinicians (range across countries 40–65%) reported using a lower dose of statin 
in patients who were unable to tolerate statins at the label-recommended dose, a 
practice which is recommended by the EASCPS. On average, 52% of patients known 
to have SAS continued to receive a low-dose statin, usually with other lipid-lowering 
therapies (LLTs). Of the remaining 48%, 37% received alternative LLT only and an 
average of 11% of patients with SAS received no statin or alternative LLT. Ezetimibe 
was the most common first choice of non-statin LLT for patients with SAS, either 
without concomitant statins (average across countries 74% clinicians) or in com-
bination with a low-dose statin as recommended by the EASCPS (average across 
countries 79% clinicians). Ezetimibe is recommended by most national and regional 
HTA agencies in the surveyed countries despite some agencies’ concerns about 
the limitations of the supporting evidence. ConClusions: This survey identified 
potential treatment gaps in the management of patients with SAS: in some cases 
patients receive no LLT, leaving them without treatment for hypercholesterolemia.
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objeCtives: ST2 reflects activity of the cardioprotective signal and it is a prognostic 
marker in heart failure. The aim is to assess the effectiveness of the ST2 for determi-
nation of the prognosis of patient with heart failure. Methods: We searched the 8 
Korean databases and overseas databases including Ovid-MEDLINE, Ovid-EMBASE and 
Cochrane Library. Total 365 studies were searched and 19 studies were included in the 
final assessment. Each of the stages from literature search and extraction of data were 
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objeCtives: Pharmacogenetic (PG) algorithms of warfarin dosing have been proposed 
as potential improvement of anticoagulation control. Despite several randomized clin-
ical trials, the clinical benefit was not consistently proven. The objective of this study 
was to estimate the opportunity cost of introduction of warfarin PG testing into health 
system using an expected value of perfect information (EVPI) approach. Methods: 
Previously developed cost-effectiveness model was employed to evaluate the PG 
algorithm-based warfarin dosing versus standard treatment. Differences in antico-
agulation control, in terms of percentage of time in therapeutic range (TTR), were used 
to simulate thromboembolic and haemorrhagic events. The outcomes were valued 
in quality-adjusted life-years (QALY) and 2014 cost. Uncertainty in the model param-
eters was assessed using probabilistic sensitivity analysis and EVPI was estimated 
at a threshold of 25,000 EUR/QALY gained. Results: In the base case, where price 
of PG test was 40 EUR, the ICER of genotype-guided treatment was 8.146 EUR/QALYg 
compared to the standard treatment. When uncertainty about clinical efficacy was 
examined, ICER ranged from approximately 1.000 EUR/QALYg to dominated strategy. 
Another important factor was the price of PG test. In the base case, the treatment 
using PG algorithm had highest expected net-benefit with opportunity loss surround-
ing uncertainty about clinical efficacy of 2.9 EUR per treated patient. Conversely, 
increasing the cost of PG test by 3 times, to 120 EUR, resulted in the highest total 
expected net-benefit for standard treatment. Selecting the genotype-guided treat-
ment instead of standard therapy would result in opportunity loss of 47.2 EUR, while 
EVPPI for standard treatment was 0.82 EUR. ConClusions: The price of PG test is 
an important factor about decision of warfarin PG introduction into health system 
or investment into additional clinical trials. The smaller cost of PG test means lower 
opportunity cost, consequentially future research should not have important impact 
on economic aspect of decision.
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objeCtives: In the prescription of pharmaceutical therapies for the chronic dis-
eases there is the responsibility both the hospital specialist doctor and the one 
territorial. A responsibility that can not be distinguished by the enterprise informa-
tion systems. Purpose of the study is the development of an informatic framework 
to implement specific training plans on the hospital’s doctors in order to reduce 
the prescription of the ACE-inhibitors compared to the ARBs. Methods: It has 
been used 2014 data of pharmaceutical prescriptions of ACE-inhibitors and ARBs, 
outpatient specialistic for cardiology visits, of hospital admissions by the Polyclinic 
of Modena, in an observational cohort study of record linkage, identifying for each 
outpatient service and of hospitalization the pharmaceutical prescription 30 days 
later 60 days prior the hospital activity. Results: It has been analysed 3,5 Billion 
outpatient prescriptions and 27.529 hospitalizations, noting that naive patients 
have received 51% of ACE-inhibitors, 64% of patients has changed his own ther-
apy from ARBs to ACE-inhibitors, while 28% has a stable therapy after cardiology 
visits. ConClusions: The model has allowed to distinguish the pharmaceutical 
therapy accomplished by the hospital’s doctors compared to the one of the doc-
tors of general medicine, highlighting also the therapies changed by the doctors of 
general medicine, in the absence of a focused informative system. The new data 
framework will support a face to face training.
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objeCtives: To investigate whether usage patterns differ for different indications 
of angiotensin converting enzyme inhibitors (ACE-inhibitors). Methods: Patients 
older than 45 years who started ACE-inhibitor treatment between January 2007 
and January 2014 were selected in the Clinical Practice Research Datalink (CPRD). 
Indications for ACE-inhibitor treatment were retrieved from the medical records. 
Stratified by indication we distinguished between continuous use, discontinued 
use, switch to an alternative drug, and restart, considering a 6 months’ time interval 
between two prescription periods. Five-years persistence rates among the differ-
ent indications were calculated using the Kaplan-Meier method and compared by 
the log-rank test. Results: In total 276,977 patients initiating ACE-inhibitors were 
identified with the following indications: hypertension (56.9 %), myocardial infarc-
tion (4.3%), renal failure (3.7%), heart failure (1.6%), combinations of them (17%) and 
none of the above (16.5%). Five-year persistence rates ranged from 44.1% for renal 
failure to 68.9% for myocardial infarction (p< 0.0001). Heart failure and renal failure 
patients used ACE-inhibitors for the shortest period of time (average 21.8 and 21.9 
months, respectively). Within the discontinuation group the percentages of switch-
ers ranged from 35.9% for renal failure to 53.9% for hypertension (61.0% switched to 
an angiotensin II-receptor blocker) and for the restarter group ranged from 15.0% for 
heart failure to 18.1% for the group without indication retrieved. ConClusions: 
Dependent on the indication the rates of ACE-inhibitor discontinuation differ. 
Patients with renal failure are most likely to discontinue treatment.
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objeCtives: Japan has universal health coverage, and, regulations concerning med-
ical reimbursements are loose in the prescription, with physicians having a high 
degree of discretion in prescriptions. There is no upper limit or reference pricing, and 
as both physicians and patients prefer brand drugs, there has been a lack of progress 
a patient with stroke lives and which factors most influence survival in stroke 
in Turkey. Methods: Based on Elixhauser Comorbidity Index, data for patients 
diagnosed at least with stroke or 17 chronic diseases such as hypertension, diabe-
tes, heart diseases were collected from Turkish SocSecurity Institution database 
between 2008 and 2013. Then with simple random sampling method, a sample of 
2,113 ischemic stroke and 155 hemorrhagic stroke patients were selected. Two Cox 
regression models were run to identify which factors impact the survival years and 
how much they reduce survival for each stroke type. Finally survival months were 
calculated. Results: Among dead patients, a patient with stroke lived less than a 
year on average. 14%, 11%, 11% and 14% percent of stroke patients died 1-2 years, 2-3 
years, 3-4 years and more than 4 years respectively. In the first model the average 
survival month for an ischemic stroke patient was 35. Age and gender didn’t change 
survival months statistically. Hypertension, diabetes, heart disease and nervous 
system diseases reduced survival months by 4, 12, 7 and 9 months respectively with 
95% confidence level. In the second model a hemorrhagic patient lived 39 months 
on average. A patient younger than 55 experienced 10 months longer lives than a 
patient over 55. Gender again didn’t incorporate any chance to survival. In addi-
tion, a patient with no hypertension and heart disease enjoyed 24 and 19 months 
longer lives respectively. ConClusions: In Turkey, the chance of living longer for 
ischemic stroke patients drops if the patients were diagnosed with hypertension, 
diabetes, heart disease or nervous system disease. Older patients with hemorrhagic 
stroke lived less, hypertension and heart disease adversely affected survival months.
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objeCtives: Stroke is a severe disease that leads one of the main causes of death and 
disability affecting approximately 15 million people worldwide. This study aims at 
analyzing summary statistics of stroke in Turkey. Methods: Data was collected for 
the patients diagnosed with stroke from Turkish Social Security Institution database 
between 2008 and 2013. Prevalence, gender and age distribution of the disease were 
computed. Then basic statistics of each type of the disease were analyzed. Results: 
Between 2008 and 2013 1.9 million people were diagnosed with stroke. Among those 
patients, 44% and 56% were males and females respectively. Over 6 years roughly 400 
thousand diagnosed patients died and as of December 31, 2013 nearly 1.5 million peo-
ple had stroke with a prevalence of 2%. The prevalence for females (2.2%) was higher 
than that of males (1.7%), higher for 0-74 age group but lower for 75+. The prevalence 
rises as age increases, 75+ population had 62, 12, 2 times higher risk of having stroke 
compared to 0-25, 35-44 and 55-64 age groups. In our study, stroke is divided into four 
subgroups: ischemic stroke, sequels, hemorrhagic stroke and unknown stroke. 84% 
of all cases was recorded as ischemic stroke (getting the largest share parallel to the 
literature), 9% as sequels, 5% hemorrhagic stroke and only 2% is unknown stroke. 
While 0-44 age group aggregated 13.2% of all ischemic stroke patients, the figure hiked 
28.1% for hemorrhagic stroke patients. ConClusions: Stroke is one of the leading 
causes of death in Turkey and the prevalence in 2013 totaled 2% of Turkish population. 
Considering that Turkey is aging rapidly in spite of having a young population, the 
number of cases with stroke will grow in near future, signaling higher stroke related 
death figures if no action is taken.
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objeCtives: Coronary heart disease (CHD) treatment has seen significant improve-
ments due to new health technologies (HT) in interventional cardiology. Health sys-
tems (HS) adopt new HT at different speed and use rates, which may become more 
apparent when contrasting between HS with distinct features. We characterized and 
compared the ability of the HS of United States (US) and Portugal (PT) to access and 
use new HT to treat CHD. Methods: A total of 30 HT between January 1980 and 
February 2015, including medical devices and active substances, were identified by 
experts and reviewed. Approval/commercialization dates of the first medical devices 
models and active substances brands were abstracted using databases at the local 
regulatory agencies and complemented with other sources of information when nec-
essary. Differences between dates were used for comparison between countries. We 
additionally performed an extensive literature review and retrieved information on 
use trends of these HT in PT versus US. Results: Most medical devices reviewed were 
approved earlier in PT than in US (median time difference: 27 months), whereas drugs 
were more readily available in US (median time difference: 61 months). Furthermore, 
while all HT are currently approved in PT, the drug-eluting balloon, Nicorandil and 
Ivabradine lack approval in US. Utilization patterns vary across devices but evidence 
suggests that adoption in PT is sometimes deferred from approval and that the US 
generally reaches similar or higher utilization rates than PT. Commercialization of 
drugs in PT was delayed by a median of 65 months from approval. ConClusions: 
Regulatory mechanisms of approval and price controls are determinant in the type of 
HT available. However, other factors appear to play an important role in the diffusion 
of new HT. Differences in use could be explored for mutual benefit for assessing and 
monitoring safety and cost-effectiveness of HT between the two HS.
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